Alk-Positive Large B-Cell Lymphoma

3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione hydrochloride, 5-(4,6-dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine, Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus, Autologous CD4+ and CD8+ T cells expressing a CD19-specific chimeric antigen receptor, Autologous engineered anti -CD19 Chimeric Antigen Receptor (CAR +) T -cells ( KYMRIAH ), Axicabtagene ciloleucel ( YESCARTA ), Brentuximab vedotin ( ADCETRIS ), Enzastaurin hydrochloride, Everolimus ( AFINITOR, VOTUBIA ), Humanised Fc engineered monoclonal antibody against CD19, Humanised anti-CD37 monoclonal antibody conjugated to maytansinoid DM1, Ibrutinib ( IMBRUVICA ), Iodine (131I) tositumomab, Lenalidomide ( LENALIDOMIDE ACCORD, REVLIMID ), Mocetinostat, Obinutuzumab ( GAZYVA, GAZYVARO ), Pixantrone dimaleate ( PIXUVRI ), Polatuzumab vedotin ( POLIVY ), Pralatrexate ( FOLOTYN ), Recombinant histidine-tagged idiotype immunoglobulin Fab fragment of clonal B-cell receptors, Rituximab ( BLITZIMA, MABTHERA, TRUXIMA, RITEMVIA, RITUXAN, RITUZENA, RIXATHON, RIXIMYO, Ruxience ), Selinexor ( XPOVIO ), Tazemetostat ( TAZVERIK ), Valproic acid, sodium, Venetoclax ( VENCLEXTA, VENCLYXTO ), haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate